The influence of serum aldosterone and the aldosterone-renin ratio on pulse wave velocity in hypertensive patients

Journal of Hypertension

Volumn 25, Issue 6, 2007, Pages 1279-1283

  Park, Sungha ^a   Kim, Jin Bae ^a   Shim, Chi Young ^a   Ko, Young Guk ^a   Choi, Donghoon ^a   Jang, Yangsoo ^a   Chung, Namsik ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Aldosterone; Hypertension; Pulse wave velocity; Renin

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RENIN; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; AGED; ALDOSTERONE BLOOD LEVEL; ARTERY COMPLIANCE; ARTICLE; BODY MASS; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; ENZYME ACTIVITY; FEMALE; HEART RATE; HUMAN; HYPERTENSION; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULSE WAVE; SEX DIFFERENCE; SITTING; SYSTOLIC BLOOD PRESSURE;

EID: 34250321620     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3280f31b6e     Document Type: Article

References (30)

1. Laurent S, Katsahian S, Fassot C, Marchais SJ, Safar ME, Tropeano AI, et al. Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke 2003; 34:1203-1206.
2. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM, et al. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999; 99:2434-2439.
3. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001; 37:1236-1241.
4. O'Rourke MF, Nichols WW. Aortic diameter, aortic stiffness, and wave reflection increase with age and isolated hypertension. Hypertension 2005; 45 (Pt 2):652-658.
5. Laurent S, Boutouyrie P, Lacolley P. Structural and genetic bases of arterial stiffness. Hypertension 2005; 45:1050-1055.
6. Zieman SJ, Melenovsky V, Kass DA. Mechanism, pathophysiology and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol 2005; 25:932-943.
7. Johnson CP, Baugh R, Wilson CA, Burns J. Age related changes in the tunica media of the vertebral artery: implications for the assessment of vessels injured by trauma. J Clin Pathol 2001; 54:139-145.
8. Lakatta EG. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part III: cellular and molecular clues to heart and arterial aging. Circulation 2003; 107:490-497.
9. Mahmud A, Feely J. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension. Am J Hypertens 2005; 18:50-55.
10. Schmidt BMW, Schmieder RE. Aldosterone induced cardiac damage: focus on blood pressure independent effects. Am J Hypertens 2003; 16:80-86.
11. Lacolley P, Labat C, Pujol A, Delcayre C, Benetos A, Safar M. Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone. Circulation 2002; 106:2848-2853.
12. Nehme JA, Lacolley P, Labat C, Challande P, Robidel E, Perret C, et al. Spironolactone improves carotid artery fibrosis and distensibility in rat postischaemic heart failure. J Mol Cell Cardiol 2005; 39:511-519.
13. Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 2001; 37:699-705.
14. Nishizaka MK, Pratt-Ubunama M, Zaman MA, Cofied S, Calhoun DA. Validity of plasma aldosterone-to-renin activity ratio in African American and White subjects with resistant hypertension. Am J Hypertens 2005; 18:805-812.
15. Blacher J, Amah G, Girerd X, Kheder A, Ben Mais H, London GM, Safar ME. Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. Am J Hypertens 1997; 10:1326-1334.
16. Kim JS, Kang TS, Kim JB, Seo HS, Park S, Kim C, et al. Significant association of C-reactive protein with arterial stiffness in treated non-diabetic hypertensive patients. Atherosclerosis (in press).
17. Kimoto E, Shoji T, Shinohara K, Inaba M, Okuno Y, Miki T, et al. Preferential sitffening of central over peripheral arteries in type 2 diabetes. Diabetes 2003; 52:448-452.
18. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissman P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40:892-896.
19. Seifarth C, Trenkel S, Schobel H, Hahn EG, Hensen J. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism. Clin Endocrinol 2002; 57:457-465.
20. Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, Veglio F. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002; 40:897-902.
21. Matsumura K, Fujii K, Oniki H, Oka M, Iida M. Role of aldosterone in left ventricular hypertrophy in hypertension. Am J Hypertens 2006; 19:13-18.
22. Struthers AD. The clinical implications of aldosterone escape in congestive heart heart failure. Eur J Heart Fail 2004; 6:539-545.
23. Duprez DA. Role of renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review. J Hypertens 2006; 24:983-991.
24. Martinez-Lemus LA, Hill MA, Bolz SS, Pohl U, Meininger GA. Acute mechanoadaptation of vascular smooth muscle cells in reponse to continuous arteriolar vasoconstriction: implications for functional remodeling. FASEB J 2004; 18:708-710.
25. Izzard AS, Rizzoni D, Agabiti-Rosei E, Heagerty AM. Small artery structure and hypertension: adaptive changes and target organ damage. J Hypertens 2005; 23:247-250.
26. Rizzoni D, Porteri E, Castellano M, Bettoni G, Muiesan ML, Muiesan P, et al. Vascular hypertrophy and remodeling in secondary hypertension. Hypertension 1996; 28:785-790.
27. Rizzoni D, Muiesan ML, Porteri E, Salvetti M, Castellano M, Bettoni G, et al. Relations between cardiac and vascular structure in patients with primary and secondary hypertension. J Am Coll Cardiol 1998; 32:985-992.
28. Lombes M, Oblin ME, Gasc JM, Baulieu EE, Farman N, Bonvalet JP. Immunohistochemical and biochemical evidence of a cardiovascular mineralcorticoid receptor. Circ Res 1992; 71:503-510.
29. Doi S, Abalkhail S, Al-Qudhaiby MM, Al-Humood K, Hafez MF, Al-Shoumer K. Optimal use and interpretation of the aldosterone renin ratio to detect aldosterone renin ratio to detect aldosterone excess in hypertension. J Hum Hypertens 2006; 20:482-489.
30. Lim PO, Rodgers P, Cardale K, Watson AD, MacDonald TM. Potentially high prevalence of primary aldosteronism in a primary care population [letter]. Lancet 1999; 353:40.